3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
38
Phase 1
13
Phase 3
9
Phase 1/2
6
Phase 4
4
Phase EARLY_PHASE1
2
Phase 2/3
2
Phase NA
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Sarcoma
1
Conditions
Ovarian Carcinosarcoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Interventions
Paclitaxel
12
Carboplatin
11
Cisplatin
9
Letrozole
6
Drug Therapy
6
liposomal doxorubicin
5
Megestrol Acetate
4
Bevacizumab
4
spartalizumab
3
Topotecan
3
Taxes
3
Medroxyprogesterone Acetate
3
olaparib
2
niraparib
2
atezolizumab
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Imiquimod
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Doxorubicin
2
1-dodecylpyridoxal
2
trametinib
1
sintilimab
1
saracatinib
1
ricin A-GnRH conjugate
1
pertuzumab
1
pembrolizumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
niraparib
×
Gynecologic
×
Clear all
NCT03651206
2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3
Recruiting
138 enrolled
NCT04159155
2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3
Terminated
11 enrolled